De Lean A, Rouleau D, Lefkowitz R J
Life Sci. 1983 Sep 5;33(10):943-54. doi: 10.1016/0024-3205(83)90750-6.
We report the development and application of a novel assay for high affinity binding of the agonist [3H]hydrozybenzyl-isoproterenol simultaneously with the agonist-promoted release of membrane bound [32P]GDP in the frog erythrocyte beta-adrenergic receptor system. We find that under various assay conditions both events occur with the same rate, ranging from 0.05 to 0.5 min-1. Addition of the non-hydrolyzable guanine nucleotide, guanylyl-imidodiphosphate simultaneously increases the rate of high affinity agonist binding and agonist promoted GDP release. In addition, the guanine nucleotide analog decreases the steady state level of high affinity agonist binding and increases the steady state level of agonist promoted GDP release with comparable potencies of 0.5 microM and 0.1 microM, respectively. The decrement in the steady state level of high affinity agonist binding (180 fmol/mg protein) due to the guanine nucleotide analog is in the same range as the reciprocal increment in the extent of agonist-induced [32P]GDP release (180 fmol/mg protein). The concommittant activation of adenylate cyclase, by submaximal concentrations of the agonist [3H]hydroxybenzylisoproterenol and guanylylimido-diphosphate under similar assay conditions proceeds with the same rate as for the two other measured functions of the system, i.e. 3H-agonist binding and agonist-promoted [32P]GDP release. This represents the first attempt at comparing the time course of adenylate cyclase activation with that of agonist binding and GDP release under similar assay conditions. The results indicate that GDP is not released prior to but rather coincident with formation of the complex of the hormone receptor with the regulatory protein and that enzyme activation proceeds with the same time course as agonist binds to the receptor. It is concluded that both high affinity agonist binding and GDP release represent integral aspects of the rate limiting step in the enzyme activation mechanism.
我们报告了一种新型测定法的开发与应用,该方法用于在青蛙红细胞β - 肾上腺素能受体系统中,同时检测激动剂[³H]羟基苄基异丙肾上腺素的高亲和力结合以及激动剂促进的膜结合[³²P]GDP释放。我们发现,在各种测定条件下,这两个事件以相同的速率发生,范围为0.05至0.5分钟⁻¹。添加不可水解的鸟嘌呤核苷酸鸟苷酰亚胺二磷酸同时增加了高亲和力激动剂结合的速率以及激动剂促进的GDP释放速率。此外,鸟嘌呤核苷酸类似物分别以0.5微摩尔和0.1微摩尔的相当效力降低了高亲和力激动剂结合的稳态水平,并增加了激动剂促进的GDP释放的稳态水平。由于鸟嘌呤核苷酸类似物导致的高亲和力激动剂结合稳态水平的降低(180飞摩尔/毫克蛋白质)与激动剂诱导的[³²P]GDP释放程度的倒数增加(180飞摩尔/毫克蛋白质)处于相同范围内。在类似的测定条件下,次最大浓度的激动剂[³H]羟基苄基异丙肾上腺素和鸟苷酰亚胺二磷酸对腺苷酸环化酶的伴随激活与该系统的另外两个测量功能,即³H - 激动剂结合和激动剂促进的[³²P]GDP释放,以相同的速率进行。这是首次尝试在类似的测定条件下比较腺苷酸环化酶激活的时间进程与激动剂结合和GDP释放的时间进程。结果表明,GDP不是在激素受体与调节蛋白形成复合物之前释放,而是与该复合物的形成同时发生,并且酶激活与激动剂与受体结合的时间进程相同。结论是,高亲和力激动剂结合和GDP释放均代表酶激活机制中限速步骤的组成部分。